Aripiprazole
| Evidence Level: L1 | Predicted Indications: 10 |
Table of Contents
Aripiprazole: From Schizophrenia and Bipolar Disorder to Major Affective Disorder
One-Sentence Summary
Aripiprazole is an atypical antipsychotic originally used for schizophrenia, bipolar disorder and autism-spectrum-related conditions. The TxGNN model predicts it may be effective for major affective disorder (in practice, major depressive disorder as add-on treatment), with 35 clinical trials and 19 publications currently supporting this direction, including several completed Phase 3 randomized trials.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Schizophrenia, bipolar disorder (including manic episodes), autism spectrum disorder (from the knowledge-graph indication list; Singapore licence indication text is not available) |
| Predicted New Indication | Major affective disorder |
| TxGNN Prediction Score | 99.62% |
| Evidence Level | L1 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 14 |
| Recommended Decision | Proceed with Guardrails |
Why is This Prediction Reasonable?
Aripiprazole is a partial agonist at dopamine D2/D3 receptors and at serotonin 5-HT1A receptors, and an antagonist at 5-HT2A receptors. Detailed mechanism-of-action data were not available in the compiled drug record, so this description comes from the mechanistic rationale prepared for the prediction. Together, these actions may adjust dopamine and serotonin signalling in mood-regulating brain circuits and strengthen the response to serotonergic antidepressants.
Bipolar disorder is itself a major affective disorder, and aripiprazole is already used for it. Depressive episodes and manic episodes share overlapping neurochemical pathways. Adding aripiprazole to an antidepressant is therefore a natural step for patients whose depression has not responded adequately. Reviews also note that several atypical antipsychotics, aripiprazole among them, have been approved in the US as add-on treatment for major depressive disorder.
Clinical Trial Evidence
Of the 35 trials retrieved, the 10 most relevant are listed below.
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT00095823 | Phase 3 | Completed | 1200 | 14-week double-blind, placebo-controlled trial of add-on aripiprazole in MDD with inadequate antidepressant response |
| NCT00095758 | Phase 3 | Completed | 1151 | 14-week double-blind, placebo-controlled trial of add-on aripiprazole in MDD |
| NCT00105196 | Phase 3 | Completed | 349 | 14-week double-blind, placebo-controlled study of add-on aripiprazole in MDD |
| NCT00683852 | Phase 3 | Completed | 225 | Double-blind, placebo-controlled study of reduced-dose aripiprazole added to antidepressant therapy in MDD |
| NCT00876343 | Phase 3 | Completed | 586 | Placebo-controlled study of aripiprazole added to an SSRI or SNRI in MDD |
| NCT01421342 | Phase 3 | Completed | 1522 | VAST-D: aripiprazole augmentation vs bupropion augmentation vs switch to bupropion in veterans with MDD |
| NCT00095745 | Phase 3 | Completed | 1002 | 52-week open-label safety and tolerability study of add-on aripiprazole in MDD |
| NCT00882362 | Phase 3 | Completed | 155 | Long-term safety and efficacy of aripiprazole added to an SSRI or SNRI in MDD |
| NCT01111539 | Phase 3 | Terminated | 211 | Randomized double-blind study of an aripiprazole/escitalopram combination in MDD; ended early, so interpretation is limited |
| NCT01488266 | N/A | Unknown | 90 | Aripiprazole augmentation vs switching antidepressant class in partial responders with MDD |
Other trials examined bipolar depression (for example NCT00080314, a completed Phase 3 trial with 400 participants), treatment-resistant late-life depression, and postpartum depression.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 42090141 | 2026 | Systematic review / network meta-analysis | JAMA Psychiatry | Adjunctive antipsychotics in MDD; the FDA has approved 5 atypical antipsychotics for this use |
| 42283956 | 2026 | Network meta-analysis | Advances in Therapy | Compares lumateperone with other approved adjunctive atypical antipsychotics in MDD |
| 34986373 | 2022 | Systematic review / network meta-analysis | J Affect Disord | Efficacy and discontinuation of augmentation agents in treatment-resistant depression |
| 35861202 | 2023 | Systematic review / meta-analysis | J Psychopharmacol | Augmentation and combination treatments for early-stage treatment-resistant depression |
| 34238049 | 2021 | Systematic review / meta-analysis | J Psychopharmacol | Antidepressant plus second-generation antipsychotic vs esketamine vs lithium in major depression |
| 39739012 | 2025 | Systematic review / network meta-analysis of RCTs | Neuropsychopharmacology | Relative effectiveness of antidepressant treatments in treatment-resistant depression |
| 38454079 | 2024 | Randomized clinical trial | Mol Psychiatry | ASCERTAIN-TRD: aripiprazole or rTMS augmentation vs switching to venlafaxine |
| 37149344 | 2023 | Review | Psychiatr Clin North Am | Atypical antipsychotics are the most widely studied augmentation agents in treatment-resistant depression |
| 36855876 | 2023 | Review | Am J Psychiatry | Role of antipsychotics in the treatment-resistant depression landscape |
| 37815563 | 2023 | Review | JAMA | Diagnosis and treatment of bipolar disorder |
Note: one meta-analysis on aripiprazole or bupropion augmentation (PMID 38669232) has been retracted and is not relied on here.
Singapore Market Information
Aripiprazole has 14 valid single-ingredient registrations in Singapore, none cancelled. Approved indication text was not available for these licences. The five main authorizations are listed below.
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN17222P | Abilify Asimtufii prolonged-release suspension for injection 960 mg/3.2 mL | Extended-release injectable suspension | Not available |
| SIN16832P | Abilify Maintena powder and solvent for prolonged-release suspension for injection 400 mg | Extended-release injectable powder for suspension | Not available |
| SIN16120P | Abilify Oral Solution 1 mg/mL | Solution | Not available |
| SIN13006P | Abilify Tablet 5 mg | Tablet | Not available |
| SIN16688P | Aripdon Tablets 5 mg | Tablet | Not available |
Available forms include oral tablets, oral solution, and long-acting injectables.
Safety Considerations
Contraindications flagged in the knowledge graph (taken from drug-disease network links, not from label text, and to be confirmed against the package insert): conditions of particular note include
- Metabolic: diabetes mellitus, hyperglycemia, diabetic ketoacidosis, hyperlipidemia, obesity
- Cardiovascular: myocardial infarction, coronary artery disease, orthostatic hypotension, heart conduction disease, sudden cardiac arrest, cerebrovascular disorder
- Haematological: neutropenia, agranulocytosis, leukopenia
- Neurological: epilepsy, neuroleptic malignant syndrome
Drug interactions: 100 interactions were found. The first 20 retrieved include one Major interaction, with bupropion, and moderate interactions with, for example:
- antidiabetic agents (metformin, pioglitazone, acarbose, alogliptin, canagliflozin)
- anticholinergics (atropine, hyoscyamine)
- CYP-inhibiting drugs (clarithromycin, cimetidine)
- cisapride
Note that bupropion is often used alongside aripiprazole in depression treatment, so this pairing needs particular attention.
Other predicted indications: aripiprazole has been linked to impulsive-compulsive behaviors, and to trichotillomania as an adverse event.
Please refer to the package insert for key warnings and formal contraindications.
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale: Several large, completed, placebo-controlled Phase 3 trials and recent network meta-analyses support add-on aripiprazole in major depressive disorder. The drug is already marketed in Singapore in 14 registrations. However, the Singapore approved-indication text and package-insert safety data are missing, and the knowledge graph lists many metabolic, cardiovascular and haematological cautions.
To proceed, the following is needed:
- Singapore package-insert warnings, contraindications and approved indications from HSA, to confirm whether depression is already covered
- Detailed mechanism-of-action data from DrugBank
- A safety monitoring plan covering metabolic parameters, blood counts and cardiovascular risk, with an interaction review for bupropion and CYP-inhibiting drugs
- A dosing strategy for adjunctive use, as the trials point to low doses
Other Predictions (Lower Priority)
| Predicted Indication | TxGNN Score | Evidence Level | Decision | Comment | |------|------|------|------|------| | Trichotillomania | 99.26% | L3 | Research question | Two small trials (one open-label, n=12; one placebo-controlled Phase 2, not yet recruiting) and case reports suggest benefit, but aripiprazole has also been linked to impulsive-compulsive behaviors, so the risk-benefit balance is unclear | | Asperger syndrome, susceptibility to | 99.52% | L5 | Hold | No studies for this entry; related support comes only from the approved autism-related indication | | Phelan-McDermid syndrome | 99.44% | L5 | Hold | Inferred from autism-spectrum features; no studies | | Gaze palsy, familial horizontal, with progressive scoliosis; amelocerebrohypohidrotic syndrome; distal 17p13.3 microdeletion syndrome; Malan overgrowth syndrome; retinal dystrophy; hydranencephaly | 99.2–99.6% | L5 | Hold | Computational prediction only; no studies and no plausible mechanistic link |
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.